NEW BRUNSWICK, N.J. (AP) -- Johnson & Johnson said Friday it has asked U.S. and European Union regulators to grant broader marketing approval for its cancer pill Zytiga.

Zytiga was approved in 2011 for the treatment of advanced prostate cancer in men who have received chemotherapy and who have not been helped by other hormone-blocking drugs. On Friday Johnson & Johnson said it asked regulators to approve Zytiga for men who have not been helped by hormone treatment but have not yet been treated with chemotherapy, and who have few or no symptoms from their cancer.

Earlier this month Johnson & Johnson reported strong results from a clinical trial involving men who had received hormone treatment and not chemotherapy. The company said Zytiga doubled the amount of time patients lived without their cancer getting worse.

Johnson & Johnson shares rose 29 cents to $65.74 in morning trading.